StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > Correction

<< Previous

Bullboard Posts

Next >>

Comment by Str8Shuteron Jun 22, 2023 7:47pm

86 Views

Post# 35510370

RE:RE:RE:RE:Correction

FWIW, I think I had better correct my earlier statement as follows, since the temporary re-pricing doesn't apply to the tradeable warrants, as LL pointed out.

With 8 SZLS.WT warrant redemptions required to purchase a single SZLS share at $0.72, the 896,000 warrants on the Ask represent the rights to purchase a total of 112,000 shares of SZLS for $80,640.

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages